Current Environment:

Researcher | Research Overview

Dr. Stacy Croteau's primary clinical research focus investigates the impact of integration of individualized pharmacokinetic (PK) profiles for hemophilia patients on bleed rates, factor concentrate utilization, and health- and patient-reported outcomes. Her current projects include characterizing real-world use of factor concentrates and assessing the feasibility of routine integration of PK data into clinical hemophilia care. She serves as the overall PI and site PI for several hemophilia clinical research trials, both industry-sponsored and investigator-initiated. She has served as a clinical research and early career mentor for several individuals spanning nurse practitioners and the undergraduate, medical school, and fellowship trainee continuum.


Researcher | Research Background

Dr. Stacy Croteau is a pediatric hematologist and clinical researcher at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, where she specializes in bleeding and clotting disorders. She completed her undergraduate and medical education at Brown University and then pursued training in Pediatrics and Pediatric Hematology/Oncology at Boston Children's Hospital and Dana-Farber Cancer Institute. Dr. Croteau joined the Boston Hemophilia Center as the associate director in 2014 and became the medical director in 2019. She enjoys clinical care of pediatric patients and leading research efforts to push the frontier of the quality and innovation in current standards of medical practice.

Dr. Croteau currently serves at the primary investigator for several industry-sponsored and investigator initiated clinical trials and as the national chair of the American Thrombosis Hemostasis Network (ATHN)/National Hemophilia Program Coordinating Center (NHPCC) Transition Working Group. She also serves on the American Society of Hematology's Scientific Committee for Hemostasis. Her primary areas of academic interest are early drug development, advancing an approach for rationally designed personalized-prophylaxis regimens in hemophilia, and quality improvement efforts targeting patient transition from pediatric to adult care.

Selected Publications

  1. Croteau SE, Wheeler AP, Khan O, Haley KM, Borst AJ, Lattimore S, Yeung CHT, Iorio A. Pharmacokinetic-tailored approach to hemophilia prophylaxis: Medical decision making and outcomes. Res Pract Thromb Haemost. 2020 Feb; 4(2):326-333. PMID: 32110764.
  2. McEneny-King A, Yeung CH, Edginton AN, Iorio A, Croteau SE. Clinical application of Web Accessible Population Pharmacokinetic Service-Hemophilia (WAPPS-Hemo): Patterns of blood sampling and patient characteristics among clinician users. Haemophilia. 2020 Jan; 26(1):56-63. PMID: 31742831.
  3. Croteau SE, Cheng D, Cohen AJ, Holmes CE, Malec LM, Silvey M, Thornburg CD, Wheeler AP, Kouides PA, Raffini LJ, Neufeld EJ. Regional variation and cost implications of prescribed extended half-life factor concentrates among U.S. Haemophilia Treatment Centres for patients with moderate and severe haemophilia. Haemophilia. 2019 Jul; 25(4):668-675. PMID: 30993845.
  4. Croteau SE, Callaghan MU, Davis J, Dunn AL, Guerrera M, Khan O, Neufeld EJ, Raffini LJ, Recht M, Wang M, Iorio A. Focusing in on use of pharmacokinetic profiles in routine hemophilia care. Res Pract Thromb Haemost. 2018 Jul; 2(3):607-614. PMID: 30046766.
  5. Croteau SE, Padula M, Quint K, D'Angelo L, Neufeld EJ. Center-Based Quality Initiative Targets Youth Preparedness for Medical Independence: HEMO-Milestones Tool in a Comprehensive Hemophilia Clinic Setting. Pediatr Blood Cancer. 2016 Mar; 63(3):499-503. PMID: 26496140.
  6. Croteau SE. Evolving Complexity in Hemophilia Management. Pediatr Clin North Am. 2018 06; 65(3):407-425. PMID: 29803274.
  7. Croteau SE, Saxena K, Neufeld EJ. Correlation between dispensed and prescribed doses of factor products for bleeding disorders: can a small, centre-based pharmacy hit the mark? Haemophilia. 2015 Mar; 21(2):190-5. PMID: 25311503.
  8. Brucker WJ, Croteau SE, Prensner JR, Cullion K, Heeney MM, Lo J, McAlvin JB, Peeler K, Shah N, Yee CSK, Berry GT, Bodamer O. An emerging role for endothelial barrier support therapy for congenital disorders of glycosylation. J Inherit Metab Dis. 2020 Feb 16. PMID: 32064623. Brand Compliant Headshot

Researcher | Publications